China Biologic Pharmaceuticals (01177.HK): The phase III clinical data of pembrolizumab in combination with anlotinib as first-line treatment for non-squamous non-small cell lung cancer will be announced at ASCO in 2026.

Smart Finance News App, China Biopharmaceuticals (01177.HK) announced that its subsidiary, Zhejiang Dahuang Pharmaceutical Group Co., Ltd. (Zhejiang Dahuang), released the latest significant abstract (LBA) at the 2026 American Society of Clinical Oncology (ASCO) Conference. The abstract presented the Phase III clinical research data of the combination of Bevacizumab with platinum-based chemotherapy and sequential Bevacizumab combined with Anlotinib as first-line treatment for non-squamous non-small cell lung cancer.